Sebastian Bunk
Immatics Biotechnologies (Germany)
ORCID: 0000-0001-8381-1375Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 3 papers. Top paper: “First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors”.
Tobias A.W. Holderried, Jason J. Luke, Van K. Morris, Winfried Alsdorf, Katrin Wetzko +27 more
Dejka M. Araujo, Manik Chatterjee, Apostolia M. Tsimberidou, Tobias A.W. Holderried, Amir A. Jazaeri +35 more
Jens Fritsche, Sebastian Bunk, Andrea Mahr, Felix Unverdorben, Kevin Tosh +37 more